Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
The move could expand Novo's reach in a key obesity-drug market.
Novo Nordisk (NVO) plans to apply for Chinese regulatory approval of its oral weight-loss drug, Wego
In April, the stock faced resistance near $30 and saw selling pressure in the following weeks.
NVO stock jumps 7% in a week on U.K. approval of oral Wegovy and positive commercial updates, but competition and 2026 pressure cloud near-term outlook.
Novo Nordisk (NVO) has spent 2026 trying to convince investors that the worst is behind it. After a punishing year, the stock is finally clawing back from its lows. So, when Goldman Sachs sat down with management at a major healthcare conference this month, investors wondered if the bank would turn ...
Eli Lilly is winning the GLP-1 race right now, but it isn't resting on its laurels.
Novo Nordisk (NYSE:NVO) has received first-in-Europe approval in the UK for its daily oral Wegovy pill for chronic weight management. The decision introduces a non injectable GLP-1 option for obesity treatment in the UK market. The company plans to launch the oral Wegovy pill in additional international markets later in 2026. Novo Nordisk, trading at $43.88, is adding another product to its obesity portfolio with this UK approval of oral Wegovy. The stock is up 2.1% over the past week,...
The National Bureau of Economic Research paper's lead author hopes putting a dollar value on the benefits of GLP-1s will lead to better access
Novo Nordisk has received UK approval for its Wegovy pill, the first daily oral GLP-1 weight-loss treatment licensed in Europe. The decision follows recent launches of the oral Wegovy treatment in the US and UAE. Phase 3 and real-world data indicate weight loss outcomes comparable to injectable GLP-1 products, with a safety profile regulators consider acceptable for broader use. For investors tracking CPSE:NOVO B, this approval comes at a time when the share price is around DKK287.25 and...
Healthcare has spent 2026 on the sidelines while the rest of the market does the heavy lifting. The Health Care Select Sector SPDR Fund (NYSEARCA:XLV) is down around 1% year to date even after a 6% one-month bounce. That stagnation has left a handful of high-margin operators trading at forward multiples that look out of ... 3 Ridiculously Cheap Healthcare Stocks to Buy in June
Novo Nordisk A/S (NYSE:NVO) is one of the 7 Best Longevity Stocks to Buy Now. On June 7, 2026, Novo Nordisk A/S (NYSE:NVO) presented Phase 3 results from its Reimagine 1-3 trials, which showed significant reductions in HbA1c and weight in adults with type 2 diabetes. The Reimagine trials met their primary endpoints, showing significant […]
Thursday’s unusual options activity had plenty to choose from. However, it was the LEAPS that were really worth considering for bullish investors. Of the 28 calls over 365 days, these three quality stocks stood out.
The pharmaceutical company's flagship anti-obesity drug continues to bolster its efficacy and tolerability arguments.
NVO stock gains 3% as the United Kingdom becomes Europe's first country to approve the daily GLP-1 Wegovy weight-loss pill, overshadowing an IT security breach.
(Updates with Eli Lilly's response to a request for comment from MT Newswires.) Some employers in
There are already lengthy patient waitlists for the medication on digital health platforms.
The authorisation by the UK's Medicines and Healthcare products Regulatory Agency makes the country the third to licence the medication after the US and the UAE.
Novo Nordisk (NYSE:NVO) has received FDA approval for oral Wegovy, the first oral GLP-1 obesity treatment in the U.S. The company has begun the U.S. launch of oral Wegovy, aiming to broaden access to obesity treatment beyond injectable options. Novo Nordisk is highlighting longevity and aesthetics as future focus areas, building on research suggesting semaglutide may protect organs and reduce biological aging. Novo Nordisk enters this new phase with oral Wegovy at a time when NYSE:NVO is...
Recent performance snapshot Novo Nordisk (NYSE:NVO) has drawn investor attention after a mixed stretch for the stock, with a gain of 2.7% over the past day contrasted with a decline of 6.5% over the past month. See our latest analysis for Novo Nordisk. Zooming out, Novo Nordisk’s recent bounce comes after a softer patch, with the share price up over the past quarter but down year to date, while the 1 year total shareholder return is also lower. This suggests momentum has cooled compared with...
In the closing of the recent trading day, Novo Nordisk (NVO) stood at $43.93, denoting a +2.62% move from the preceding trading day.
Novo Nordisk (NYSE:NVO) is one of the top large cap value stocks to buy now. On June 8, Novo Nordisk presented Phase 3 results from its REIMAGINE 1–3 clinical program at the 2026 American Diabetes Association Scientific Sessions. The trials showed that the investigational treatment CagriSem, a once-weekly combination of an amylin analog and a […]
Healthcare stocks rose late Thursday afternoon, with the NYSE Healthcare Index and the State Street
Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) reported Q1 2026 results that pulled the GLP-1 duopoly apart. Lilly grew revenue 55.5% and raised guidance. Novo posted a 4% adjusted sales decline at constant currency and is cutting 9,000 jobs. Both call obesity the prize, but their quarters tell very different stories about who ... Eli Lilly vs Novo Nordisk: The Battle for Obesity Drug Supremacy
Novo Nordisk revealed that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved the Wegovy pill, following in the footsteps of the U.S. FDA.
Novo Nordisk reported an IT security incident involving unauthorized access to internal systems. Certain non public, including personal, data was copied externally, prompting notifications to affected parties. Some IT systems were taken offline in response, while the company stated that business operations were unaffected. Novo Nordisk, traded as CPSE:NOVO B, is addressing this cybersecurity incident against a backdrop of recent share price pressure. The stock closed at DKK281.2, with the...
The U.K. regulator is the third regulatory authority to license the medicine as the Danish drugmaker seeks to regain its lead in the obesity market.
Rising use of weight-loss drugs keeps pressure on health benefit costs.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
